圣湘生物：鸿鹄聚变系公司实控人戴立忠的个人投资

Core Viewpoint - The article discusses the investment of Shengxiang Biological's actual controller and chairman, Dai Lizhong, in a controlled nuclear fusion company, Shanghai Honghu Fusion, which is the first domestic enterprise focusing on high-temperature superconducting stellarator technology [1] Company Summary - Shengxiang Biological confirmed that Shanghai Honghu Fusion was established in 2023 and is founded by Dai Lizhong, who is also the actual controller of Shengxiang Biological [1] - Honghu Fusion is recognized as a leading company in the design and development of stellarator technology, which utilizes precisely designed three-dimensional high-temperature superconducting coils to generate magnetic fields without relying on plasma current [1] - Dai Lizhong does not participate in the daily operations of Honghu Fusion, aiming to provide a platform for world-class scientists and engineers in the field [1] Investment Context - The investment by Dai Lizhong is personal and does not currently involve Shengxiang Biological, with any potential investment by the listed company to be decided based on actual development needs and strategic planning [1]